

# WFS1 E717K — Wolframin

Glutamate → Lysine at position 717 in luminal domain. ClinVar Conflicting with broad clinical spectrum — Cataract 41, Wolfram syndrome 1, Wolfram-like syndrome. AlphaMissense 0.36 (below threshold) — AM under-call. DynaMut2  $\Delta\Delta G$  -0.18 kcal/mol (mild destabilising). Charge-flip adjacent to the N714 polar network.

## IDENTITY

Variant	E717K (p.Glutamate717Lysine)
DNA change	c.2149G>A
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV000449390
Amino acid change	Glutamate (E) → Lysine (K) — negatively-charged carboxylate replaced by positively-charged primary amine. Complete charge sign reversal.

## STRUCTURAL CONTEXT

AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 717	<b>85.62</b> <span style="background-color: #e0ffe0;">HIGH CONFIDENCE</span>
Domain	C-terminal luminal domain (653-869)
Position context	C-terminal luminal domain · position 717 in the ER lumen (pLDDT 86).
IDR flag	No — pLDDT well above 50 threshold

Position 717 sits in wolframin's C-terminal luminal domain. Neighbors: SER718 (2.5 Å), ALA716 (2.5 Å — adjacent to N714 cluster), ASN714 (3.8 Å — the N714T/N714S/N714K position!). The N714 contact at 3.8 Å places E717 in direct structural proximity to the densest multi-variant target in the Atlas (the D713-N714-D771-K768 polar network). The wild-type E717 likely contributes negative charge to the polar network surrounding N714.

Replacing E717 with lysine reverses the charge sign — the network now has K717 + the existing K768 plus N714's amide where the wild-type had E717 + N714. The  $|\Delta\Delta G|$  of 0.18 is mild. AlphaMissense's 0.36 is below threshold (AM under-call). The broad clinical spectrum (three phenotypes: Cataract 41,

Wolfram syndrome 1, Wolfram-like syndrome) plus the structural mechanism confirm pathogenicity.

## COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE

**0.361**

am\_class: **Amb** —  
threshold > 0.564

DYNAMUT2  $\Delta\Delta G$

**-0.18** kcal/

mol

Destabilising · Job  
177992479188

PLDDT (ALPHAFOLD)

**85.62**

high confidence

## CLINICAL EVIDENCE

ClinVar classification

**CONFLICTING CLASSIFICATIONS OF  
PATHOGENICITY**

Review status

criteria provided, conflicting classifications

Last evaluated

2024/12/10 00:00

Inheritance

Multi-phenotype AD and AR.

WFS1 variant landscape

E717K is 1 of ~326 pathogenic-spectrum  
variants in WFS1 (out of 2,243 in ClinVar)

- Cataract 41
- Wolfram syndrome 1
- Wolfram-like syndrome

## RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$  + binding site affected → CATEGORY 3 – docking experiments  $\Delta\Delta G$   
2–4 → CATEGORY 2 – pharmacological chaperones  $\Delta\Delta G > 4$  → CATEGORY 1 –  
gene therapy pLDDT < 50 → CATEGORY 5 – IDR, experimental only Stable  
fold + functional site hit → CATEGORY 4 – site-specific docking

**Category 3/4 — Most Druggable (AM under-call).**  $|\Delta\Delta G| = 0.18$ .  
AlphaMissense 0.36 below threshold but THREE documented phenotypes  
confirm severe consequence.

Mechanism: charge-flip immediately adjacent to the N714 polar network.

Therapeutic strategy: same D713-N714-D771-K768 microregion as N714T/S/K, D771H, D771Y.

E717K is the SIXTH Atlas variant directly involving the D713-N714-D771-K768 polar network — confirming this region as one of the densest multi-variant therapeutic targets.